Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.
A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.
There appears to be a dose-response protective effect of serum concentrations of 25-hydroxyvitamin D (25(OH)D) on the risk of breast cancer, such that levels of ≥60 ng/mL yield the most protection, according to a recent study.
Continued follow-up study of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) leads to successful detection of resectable tumours and high-grade precursor neoplasms, as shown in a recent study.
Surgical resection (SR) as a first-line treatment for small perivascular hepatocellular carcinoma (HCC) provides better long-term tumour control than radiofrequency ablation (RFA), a recent study has shown.
In metastatic triple-negative breast cancer (mTNBC) patients, the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios predict outcomes with platinum-based chemotherapy, according to a recent study.
Adjusting treatment strategy based on results of a PET* scan performed after two cycles of escalated BEACOPP** potentially reduces exposure to toxicity and has comparable outcomes to a standard treatment regimen in patients with advanced Hodgkin lymphoma, according to the final analysis of the phase III AHL 2011 LYSA*** trial presented at EHA 2018.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.